BROADCASTS.com

If you don\u2019t know the nuts and bolts of the current Health and Human Services (HHS) proposal to nix Pharma\u2019s ability to pay pharmacy benefit manager (PBM) rebates, then it\u2019s possible you might want to listen to EP216 with Chris Sloan first. In this episode, we don\u2019t talk much about the impact of the HHS proposal on patient premiums or drug costs. That\u2019s EP216. What we do talk about today is the impact on pharmaceutical companies. We also discuss the drug-buying transaction. Kuo Tong is my guest today. Kuo is a managing director in the life sciences practice of Navigant, focusing on how pharma companies interact with insurance companies and get reimbursement for their drugs. And that\u2019s actually the burning question we aim to answer today: Will Pharma\u2019s interactions with and reimbursement from insurance companies change after this proposed HHS rule goes into effect, assuming it goes into effect? We also talk about what Pharma could and should be doing right now to improve the odds of a smooth transition into a new contracting model.

Kuo Tong is a managing director in the life sciences practice of Navigant and oversees its US Market Access Center of Excellence. He joined the firm in November 2017 to lead a team focused on health economics, pricing, and market access engagements.\xa0